Amryt Pharma Holdings logo

AMYT - Amryt Pharma Holdings Share Price

$11.36 0.2  2.1%

Last Trade - 7:14pm

Sector
Healthcare
Size
Small Cap
Market Cap £294.8m
Enterprise Value £379.6m
Revenue £44.3m
Position in Universe 3164th / 6368
Bullish
Bearish
Unlock AMYT Revenue
Momentum
Relative Strength (%)
1m +34.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -28.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 1.49 14.4 17.1 58.1 170.9 215
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Amryt Pharma Holdings Ltd revenues increased from $17.1M to $58.1M. Net loss increased from $30.5M to $65.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Administrative, selling and marketing ex increase from $17.3M to $35.5M (expense), Restructuring and acquisition costs increase from $0K to $13M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AMYT Revenue Unlock AMYT Revenue

Net Income

AMYT Net Income Unlock AMYT Revenue

Normalised EPS

AMYT Normalised EPS Unlock AMYT Revenue

PE Ratio Range

AMYT PE Ratio Range Unlock AMYT Revenue

Dividend Yield Range

AMYT Dividend Yield Range Unlock AMYT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AMYT EPS Forecasts Unlock AMYT Revenue
Profile Summary

Amryt Pharma Holdings Limited, formerly Amryt Pharma plc, is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. Its products include AP 101 and AP102. AP101 (Episalvan) is a potential treatment for Epidermolysis Bullosa (EB), and it is in Phase III clinical trials. AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases. It holds a license to sell Lojuxta (lomitapide) for adults, across the European Union (EU) and other territories, including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated December 20, 2004
Public Since April 27, 2007
No. of Shareholders: n/a
No. of Employees: 99
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market (Dual Listing)
Shares in Issue 31,699,777
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AMYT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AMYT
Upcoming Events for AMYT
Frequently Asked Questions for Amryt Pharma Holdings
What is the Amryt Pharma Holdings share price?

As of 7:14pm, shares in Amryt Pharma Holdings are trading at $11.36, giving the company a market capitalisation of £294.8m. This share price information is delayed by 15 minutes.

How has the Amryt Pharma Holdings share price performed this year?

Shares in Amryt Pharma Holdings are currently trading at $11.36 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Amryt Pharma Holdings price has moved by % over the past year.

What are the analyst and broker recommendations for Amryt Pharma Holdings?

There are no analysts currently covering Amryt Pharma Holdings.

When will Amryt Pharma Holdings next release its financial results?

Amryt Pharma Holdings is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Amryt Pharma Holdings dividend yield?

Amryt Pharma Holdings does not currently pay a dividend.

Does Amryt Pharma Holdings pay a dividend?

Amryt Pharma Holdings does not currently pay a dividend.

When does Amryt Pharma Holdings next pay dividends?

Amryt Pharma Holdings does not currently pay a dividend.

How do I buy Amryt Pharma Holdings shares?

To buy shares in Amryt Pharma Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Amryt Pharma Holdings?

Shares in Amryt Pharma Holdings are currently trading at $11.36, giving the company a market capitalisation of £294.8m.

Where are Amryt Pharma Holdings shares listed? Where are Amryt Pharma Holdings shares listed?

Here are the trading details for Amryt Pharma Holdings:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: AMYT
What kind of share is Amryt Pharma Holdings?

Based on an overall assessment of its quality, value and momentum, Amryt Pharma Holdings is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Amryt Pharma Holdings share price forecast 2020?

Shares in Amryt Pharma Holdings are currently priced at $11.36. At that level they are trading at 0.16% discount to the analyst consensus target price of 0.00.

Analysts covering Amryt Pharma Holdings currently have a consensus Earnings Per Share (EPS) forecast of -0.1964341724 for the next financial year.

How can I tell whether the Amryt Pharma Holdings share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Amryt Pharma Holdings. Over the past six months, the relative strength of its shares against the market has been 40.98%. At the current price of $11.36, shares in Amryt Pharma Holdings are trading at 4.21% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Amryt Pharma Holdings PE Ratio?

We were not able to find PE ratio data for Amryt Pharma Holdings.

Who are the key directors of Amryt Pharma Holdings?

Amryt Pharma Holdings's management team is headed by:

Harry Stratford - NEC
Markus Ziener - NID
Joe Wiley - CEO
Rory Nealon - CFO
Ray Stafford - NID
James Culverwell - NID
Who are the major shareholders of Amryt Pharma Holdings?

Here are the top five shareholders of Amryt Pharma Holdings based on the size of their shareholding:

EdgePoint Investment Group Inc. Investment Advisor
Percentage owned: 7.65% (2.43m shares)
EdgePoint Global Growth & Income Portfolio Mutual Fund
Percentage owned: 5.25% (1.66m shares)
Allianz Global Investors U.S. LLC Investment Advisor/Hedge Fund
Percentage owned: 3.06% (971k shares)
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund
Percentage owned: 2.42% (766k shares)
Allianz Income And Growth Mutual Fund
Percentage owned: 2.29% (727k shares)
Similar to AMYT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.